GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nutra Pharma Corp (OTCPK:NPHC) » Definitions » Cash Flow from Operations

Nutra Pharma (Nutra Pharma) Cash Flow from Operations : $-0.94 Mil (TTM As of Sep. 2022)


View and export this data going back to . Start your Free Trial

What is Nutra Pharma Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Sep. 2022, Nutra Pharma's Net Income From Continuing Operations was $0.58 Mil. Its Depreciation, Depletion and Amortization was $0.02 Mil. Its Change In Working Capital was $0.13 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $-0.02 Mil. Its Stock Based Compensation was $0.00 Mil. And its Cash Flow from Others was $-0.87 Mil. In all, Nutra Pharma's Cash Flow from Operations for the three months ended in Sep. 2022 was $-0.17 Mil.


Nutra Pharma Cash Flow from Operations Historical Data

The historical data trend for Nutra Pharma's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutra Pharma Cash Flow from Operations Chart

Nutra Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.14 -1.00 -0.74 -0.88 -1.74

Nutra Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.41 -0.23 -0.26 -0.29 -0.17

Nutra Pharma Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Nutra Pharma's Cash Flow from Operations for the fiscal year that ended in Dec. 2021 is calculated as:

Nutra Pharma's Cash Flow from Operations for the quarter that ended in Sep. 2022 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nutra Pharma  (OTCPK:NPHC) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Nutra Pharma's net income from continuing operations for the three months ended in Sep. 2022 was $0.58 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Nutra Pharma's depreciation, depletion and amortization for the three months ended in Sep. 2022 was $0.02 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Nutra Pharma's change in working capital for the three months ended in Sep. 2022 was $0.13 Mil. It means Nutra Pharma's working capital increased by $0.13 Mil from Jun. 2022 to Sep. 2022 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Nutra Pharma's cash flow from deferred tax for the three months ended in Sep. 2022 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Nutra Pharma's cash from discontinued operating Activities for the three months ended in Sep. 2022 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Nutra Pharma's asset impairment charge for the three months ended in Sep. 2022 was $-0.02 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Nutra Pharma's stock based compensation for the three months ended in Sep. 2022 was $0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Nutra Pharma's cash flow from others for the three months ended in Sep. 2022 was $-0.87 Mil.


Nutra Pharma Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Nutra Pharma's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Nutra Pharma (Nutra Pharma) Business Description

Traded in Other Exchanges
N/A
Address
1537 NW 65th Avenue, Plantation, FL, USA, 33313
Nutra Pharma Corp operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. It also develops proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Some of its drug names are Cobroxin, Nyloxin, RPI-78M, RPI-MN and Pet Pain-Away.
Executives
Rik J Deitsch officer: Chief Executive Officer 4001 NW 73 WAY, CORAL SPRINGS FL 33065
Dan Oran director 8411 W OAKLAND PARK BLVD, #201, SUNRISE FL 33351
Bruno Sartori other: Former CFO 275 COMMERCIAL BLVD, STE 260, FT LAUDERDALE FL 33308
Harold Henry Rumph director, officer: President - ReceptoPharm 1537 N.W. 65TH AVENUE, PLANTATION FL 33313
David Michael Isserman officer: Chief Marketing Officer 2776 UNIVERSITY DRIVE, CORAL SPRINGS FL 33065
Garry Pottruck director 10768 NW 18TH CT, CORAL SPRINGS FL 33071
Paul F Reid director 9610 NW 24 CT, SUNRISE FL 33322
Michael Doherty director, officer: Executive Chairman
Tanvir A Khandaker director 387 PARK AVENUE SOUTH THIRD FLOOR, NEW YORK NY 10016
Stewart Alan Lonky director 1158 CHAUTAUQUA BLVD., PACIFIC PALISADES CA 90272
Stanley Jack Cherelstein director 2401 SW MANOR HILL DRIVE, PALM CITY FL 34990
Michael Flax director, officer: Chief Financial Officer 2499 BANYAN RD, BOCA RATON FL 33432
Mcclelland David C Sr director P.O. BOX 263, FINDLEY LAKE NY 14736
Mitchell S Felder director PO BOX 1332, HERMITAGE PA 16148
Khalsa Soram Singh Md director 436 N BEDFORD DR, BEVERLY HILLS CA 90210

Nutra Pharma (Nutra Pharma) Headlines

From GuruFocus

Nutra Pharma Partners with NxGen Brands for Nyloxin® Distribution

By Marketwired Marketwired 04-19-2018